News

Computers and Newspapers

Press Releases

CalciMedica Announces IDMC Recommendation to Continue with Trial Evaluating Auxora™ in Patients with Severe COVID-19 Pneumonia

LA JOLLA, Calif., December 17, 2020 – CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechnology company targeting calcium release-activated calcium (“CRAC”) channels for the …

CalciMedica Announces Publication of Preclinical Data Demonstrating the Pathological Role of Microglial CRAC Channels in Ischemic Stroke

First report of pathological role for microglial calcium activity in cortical spreading depolarization (CSD), a complication of stroke CRAC channel inhibitors represent an important future …

CalciMedica Appoints Daniel Geffken as Interim Chief Financial Officer

Mr. Geffken brings more than three decades of financial experience to CalciMedica; involved in 12 IPO filings since 2013 LA JOLLA, Calif., November 5, 2020 …

CalciMedica Announces Peer-Reviewed Publication of Positive COVID-19 Data and Initiation of Blinded, Placebo-Controlled Trial of Auxora™ in Patients with Severe COVID-19 Pneumonia

Study published in Critical Care journal shows patients with severe COVID-19 pneumonia treated with Auxora and standard of care had substantially improved outcomes compared to …

CalciMedica and EpiPharma Enter into Research Collaboration to Discover and Develop CRAC Channel Inhibitor Therapies

Under the terms of the research collaboration agreement, CalciMedica will use EpiPharma’s state of the art Pre-clinical Drug Testing and Diagnostics Laboratory Platform to accelerate …

CalciMedica Announces Data Showing Auxora™ Substantially Improved Outcomes in Patients with Severe COVID-19 Pneumonia

Median time to recovery was more than two times faster for patients treated with Auxora plus standard of care compared to standard of care alone …

CalciMedica Appoints Robert N. Wilson as Co-Chairman of the Board of Directors and Eric W. Roberts as Vice Chairman

Robert N. Wilson was Former Johnson & Johnson Vice Chairman Board Member, Eric W. Roberts, named Vice Chairman and Chairman of the Strategic Transactions and …

CalciMedica Announces Positive Topline Data from Interim Analysis of Trial Evaluating Auxora™ in Patients with Severe COVID-19 Pneumonia

Interim results showed Auxora plus standard of care improved time to recovery and reduced ventilator use in patients compared to standard of care alone  LA …

CalciMedica Raises $15 Million in Series C Financing Round Led by Valence Life Sciences

Funds to support ongoing clinical trials in patients with COVID-19 pneumonia and commercial manufacturing of Auxora™   LA JOLLA, Calif., May 22, 2020 – CalciMedica Inc. (“CalciMedica” …

CalciMedica Announces that FDA Has Strongly Recommended Moving to a Blinded Placebo-controlled Trial with Auxora™ in Patients with Severe COVID-19 Pneumonia

LA JOLLA, Calif., May 21, 2020 – CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels for the treatment …

CalciMedica Announces Independent Safety Review Committee Recommendation to Continue Phase 2 Study of CM4620-IE in Patients with Severe COVID-19 Pneumonia on Low-Flow Oxygen Therapy

LA JOLLA, Calif., May 7, 2020 – CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels for the treatment …

CalciMedica Expands Clinical Study to Assess CM4620-IE in Patients with Critical COVID-19 Pneumonia on High-Flow Oxygen Therapy

Phase 2 open-label study expands to additional sites across the U.S. and aims to enroll 120 patients  LA JOLLA, Calif., April 30, 2020 – CalciMedica Inc. …

FDA Grants CalciMedica Permission to Begin Dosing CM4620-IE in Patients with Severe COVID-19 Pneumonia under a Newly Opened IND

Regions Hospital in St. Paul, Minnesota has begun a Phase 2 clinical study of CM4620-IE in patients with severe COVID-19 pneumonia this week, and Henry …

CalciMedica to Present Results of PD/PK Study in Acute Pancreatitis Patients for Its CRAC Channel Inhibitor CM4620 at APA Annual Meeting

LA JOLLA, CA, November 7, 2019 /PRNewswire/ — Kenneth Stauderman, Ph.D., CalciMedica’s Chief Scientific Officer, is presenting a poster at the American Pancreas Association annual …

Henry Ford Hospital Physician Presents Results from the Initial Patient Study of CalciMedica’s CRAC Channel Inhibitor CM4620 in Acute Pancreatitis at ACEP Meeting

LA JOLLA, CA, October 30, 2019 /PRNewswire/ — Joseph Miller, MD, MS, a physician at the Henry Ford Health System in Detroit, MI, and a …

CalciMedica Names Life Science Veteran to Its Board of Directors

LA JOLLA, CA, March 26, 2019 /PRNewswire/ — CalciMedica, a clinical-stage biopharmaceutical company developing CM4620, a novel small molecule compound for acute pancreatitis, announced that …

CalciMedica, Inc. to Present Study Population Profile from Its Initial Patient Study of Its CRAC Channel Inhibitor CM4620 in Acute Pancreatitis at International Conference

LA JOLLA, CA, March 19, 2019 /PRNewswire/ — Physicians from several study sites involved in CalciMedica’s initial acute pancreatitis clinical study of its CRAC channel …

CalciMedica Names Two Senior Executives to Its Board of Directors

LA JOLLA, CA, May 1, 2018 /PRNewswire/ — CalciMedica announced that it named two independent members to its Board of Directors, Lakhmir Chawla, MD, currently …

Research Collaboration Between the San Francisco VA, UCSF and CalciMedica, Inc. to Present Results on CRAC Channel Inhibitors in a Stroke Model at International Conference

LA JOLLA, CA, January 24, 2018 /PRNewswire/ — Researchers from the San Francisco Veterans Affairs Medical Center and UCSF, and CalciMedica, Inc., are presenting a …

CalciMedica Receives Fast-Track Designation for CM4620, A Novel CRAC Channel Inhibitor to Treat Acute Pancreatitis

PATIENT STUDIES EXPECTED TO BEGIN IN EARLY 2018 LA JOLLA, Calif., May 24, 2017 /PRNewswire/ — Privately-held CalciMedica, Inc., announced today that it received Fast-track …

CalciMedica Initiates Phase 1 Clinical Studies for CRAC Channel Inhibitor

LA JOLLA, Calif., January 5, 2017 /PRNewswire/ — Privately-held CalciMedica, Inc., announced that it started Phase 1 safety studies in healthy volunteers of a novel …

Scroll to Top